Alogliptin: a new addition to the class of DPP-4 inhibitors
Radha Andukuri, Andjela Drincic, Marc RendellDivision of Endocrinology, Department of Medicine, Creighton University School of Medicine, Omaha, Nebraska, USABackground: Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibitio...
Main Authors: | Radha Andukuri, Andjela Drincic, Marc Rendell |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-07-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity |
Online Access: | http://www.dovepress.com/alogliptin-a-new-addition-to-the-class-of-dpp-4-inhibitors-a3367 |
Similar Items
-
Alogliptin – the new member of DPP-4 inhibitors class
by: Nina Aleksandrovna Petunina, et al.
Published: (2014-12-01) -
PRE1BRAZIL Protocol: A Randomized Controlled Trial to Evaluate the Effectiveness and Safety of the DPP-4 Inhibitor Alogliptin in Delaying the Progression of Stage 2 Type 1 Diabetes
by: Penaforte-Saboia JG, et al.
Published: (2024-02-01) -
Alogliptin: efficiency, safety, new possibilities
by: L. Yu. Morgunov
Published: (2020-05-01) -
Potent antiatherosclerotic effects of alogliptin in addition to its potent antidiabetic effects
by: Kapoor S
Published: (2012-05-01) -
Renoprotective Effects of DPP-4 Inhibitors
by: Daiji Kawanami, et al.
Published: (2021-02-01)